The oncology sector is experiencing a rapid paradigm shift, driven by the integration of immunotherapy into standard care pathways. At the forefront of this change is the evolution of Tecentriq Market Trends, which reflect a growing reliance on programmed death ligand 1 (PD L1) inhibitors to combat complex malignancies. Tecentriq has established itself as a versatile therapeutic option,...